Lewin C S
Department of Medical Microbiology, University of Edinburgh Medical School.
J Med Microbiol. 1992 May;36(5):353-7. doi: 10.1099/00222615-36-5-353.
A new 1,8-naphthyridine quinolone antimicrobial, PD131628, was found to be as, or more active than ciprofloxacin or ofloxacin against Escherichia coli and considerably more active than the two 4-quinolone agents against staphylococci in terms of both MIC and OBC (the optimum bactericidal concentration, at which the rate of kill is greatest). In common with ciprofloxacin and ofloxacin, the rate of kill of PD131628 against Enterococcus faecalis was considerably slower than against the other three species tested. Bacterial protein synthesis, RNA synthesis and cell division were not required for the bactericidal activity of PD131628 against E. coli or the staphylococci, although the lethality of PD131628 in the absence of these activities was reduced.
一种新型1,8-萘啶喹诺酮类抗菌药物PD131628,在针对大肠杆菌方面,被发现与环丙沙星或氧氟沙星活性相当或更高,并且就最低抑菌浓度(MIC)和最佳杀菌浓度(OBC,即杀菌速率最大时的浓度)而言,针对葡萄球菌的活性比这两种4-喹诺酮类药物高得多。与环丙沙星和氧氟沙星一样,PD131628对粪肠球菌的杀菌速率比对其他三种受试菌要慢得多。PD131628对大肠杆菌或葡萄球菌的杀菌活性并不需要细菌蛋白质合成、RNA合成和细胞分裂,尽管在缺乏这些活性时PD131628的致死性会降低。